Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Regulus Appoints Mark G. Foletta to its Board of Directors



          Regulus Appoints Mark G. Foletta to its Board of Directors

Mr. Foletta Brings Extensive Financial and Commercial Biotechnology Expertise

PR Newswire

LA JOLLA, Calif., Jan. 31, 2013

LA JOLLA, Calif., Jan. 31, 2013 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
appointment of Mark G. Foletta to its Board of Directors and Audit Committee,
effective immediately. 

"We are very pleased to have Mark join our Board," said John Maraganore,
Ph.D., Chairman of the Board of Directors of Regulus and CEO of Alnylam
Pharmaceuticals, Inc.  "His extensive financial and operational experience
contributed to Amylin Pharmaceuticals' success and his guidance will serve the
Regulus Board and Audit Committee well as we continue to grow the company."

"Regulus is leading the drive to use microRNA therapeutics to treat complex
human diseases and is also a well-capitalized, emerging public
biopharmaceutical company," said Mr. Foletta.  "I am excited to work with an
experienced management team and an accomplished Board as the Company prepares
to nominate its first clinical candidates."

Most recently, Mr. Foletta served as Senior Vice President, Finance and Chief
Financial Officer of Amylin Pharmaceuticals, Inc. from March 2006 through
Amylin's acquisition by Bristol Myers-Squibb Company in August 2012.  Mr.
Foletta was instrumental in the growth of Amylin's diabetes and obesity
franchises, including the commercial launch of diabetes drugs BYDUREON®,
BYETTA® and SYMLIN®.  Prior to joining Amylin in 2000, Mr. Foletta held a
number of management positions with Intermark, Inc. and Triton Group Ltd. and
served as an Audit Manager with Ernst & Young.  He is currently a member of
the Board of Directors and Audit Committee of AMN Healthcare Services, Inc. 
Mr. Foletta received a B.A. in Business Economics from the University of
California, Santa Barbara. He is a Certified Public Accountant and a member of
the Financial Executives Institute.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting microRNAs.
Regulus is leveraging a mature therapeutic platform based on technology that
has been developed over 20 years. Regulus works with a broad network of
academic collaborators and leverages the oligonucleotide drug discovery and
development expertise of its founding companies, Alnylam Pharmaceuticals and
Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward
clinical development in several areas, including oncology, fibrosis, hepatitis
C and metabolic diseases. Regulus has formed strategic alliances with
AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with
Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus.  Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect.  Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs.  These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings.  All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

BYDUREON®, BYETTA® and SYMLIN® are registered trademarks of Amylin
Pharmaceuticals, Inc.

SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., 858-202-6300,
aconrad@regulusrx.com; or Media, David Schull, Russo Partners LLC,
212-845-4271, david.schull@russopartnersllc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement